logo
NE Ohio man's ashes heading to space in otherworldly tribute: ‘Memorialize him forever'

NE Ohio man's ashes heading to space in otherworldly tribute: ‘Memorialize him forever'

Yahoo19 hours ago

CLEVELAND (WJW) – From ashes to orbit, a Northeast Ohio man who loved life and especially astronomy is being honored this weekend with an out of this world tribute.
Retired Mentor pharmacist Curtis 'Curt' Carson Lau had many interests from whale watching to bonsai trees, but especially astronomy.
He was a proud member of the Chagrin Valley Astronomical Society and often took trips to see launches at the Kennedy Space Center.
'One time I was talking to him he was like, 'I'm listening to a book on astrophysics,' like what?' said son Griffin Lau.
Lau's sons Griffin and Carson hoped to see a launch with him someday, but in July 2024 he passed away suddenly while working out at the gym just weeks after his 70th birthday.
Big winner! North Canton man wins top million dollar prize on scratch-off ticket
The boys immediately recalled a conversation with their dad about what to do with his cremains.
'We discussed planting a tree or launching a firework,' said Griffin. 'But the main one was getting launched into space… certainly knew very quickly after his passing this was something we wanted to do for him.'
The contacted Celestis, Inc. Memorial Spaceflights, co-founded three decades ago by CEO Charles Chafer.
'As a way for people around the world to experience space at a time of loss,' he said. 'It's the coolest memorial service on or off the planet.'
Chafer said this weekend's launch will take place out of Vanderberg Space Force Base. The mission is being provided by The Exploration Company, through SpaceX's SmallSat Rideshare program.
'We attach ourselves to a satellite or rocket that already has the destination that we're intending,' said Chafer.
The weekend launch will be the 25th for the company.
They've put 2,500 souls from 35 nations into space.
Prices start around $3,400 using a symbolic portion of the cremains or a DNA sample in a small capsule.
There are four destination options from the moon to deep, deep space.
A popular selection includes orbiting earth for five years and then returning like a celestial body.
'The laws of physics and gravity bring those capsules back into the atmosphere in a container that burns up entirely upon reentry creating a shooting star,' said Chafer.
'Kids just being kids': Officers invite Akron youth to day of fishing, fun
The Lau's chose an option where their dad's ashes will orbit the earth traveling 17,000 miles per hour before re-entering the atmosphere.
The capsules will then be retrieved off the coast of Alaska and returned to the families about two months after the initial launch.
'Kind of a final gift to him,' said Carson. 'He spent a lot of his later years going down to watch rocket launches and it was like, 'oh, we'll get there at some point as a family,' so in a way this is like the three of us as a family getting to do that and getting to get the capsule back after is just kind of a nice cherry on top.'
A proper farewell for a father whose life shone brighter than the stars he so loved.
'We're excited again from a closure release standpoint to have one launch together to help memorialize him further,' said Griffin.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating

Yahoo

time3 hours ago

  • Yahoo

Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an 'Outperform' rating and a $49 price target. The research firm reiterated the company's solid position amid the 'TTR craze' while also echoing its commercial execution strategy. A medical technician wearing a lab coat operating machinery in a biopharmaceutical laboratory. Consequently, Wolfe Research expects BridegBio's revenue to total $569 million in 2025 before rising to $3.4 billion by 2028. It should peak at $4.4 billion in 2034. For the upcoming second quarter, the research firm expects the company to deliver revenue of $106 million, slightly below market expectation of $111 million. While the stock has shown a remarkable return of 42% year to date, Wolfe Research insists it must navigate several challenges to maintain the positive momentum. It must navigate the potential Vyndaqel loss of exclusivity, achondroplasia data versus competition, and pipeline products. In addition, consistent revenue growth and expanding operating margins will be crucial to the company's long-term success. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases. Its pipeline includes a range of development programs, from early science to advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Yahoo

time3 hours ago

  • Yahoo

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes
Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Yahoo

time4 hours ago

  • Yahoo

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and disease progression in patients. An analysis of the STRIDE trial was presented as a late-breaking symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in Diabetes Care®. PAD is a serious condition impacting 230 million individuals globally and up to 30% of people with diabetes. PAD narrows arteries and reduces blood flow to the legs, causing marked disability, affecting quality of life, and putting people at increased risk of severe complications including amputations and death. Treatment options are currently limited, and little advancements in PAD treatment have occurred for more than 25 years. The STRIDE trial is a phase 3, multinational, double-blind, randomized clinical trial conducted at 112 outpatient clinical trial sites in 20 countries in North America, Asia, and Europe. 792 patients aged 18 years and older with type 2 diabetes and PAD with intermittent claudication (a symptom of PAD that causes muscle pain or cramping in the legs during physical activity) and reduced ankle-brachial or toe-brachial index (indicators of restricted blood flow to the legs), were randomly assigned to receive either semaglutide (n=396) or placebo (n=396) over a 52-week period to assess the impact on walking capacity, symptoms, and quality of life. The median age was 68 years, and 195 (25%) participants were female and 597 (75%) were male. The sub-analysis builds on results previously published in The Lancet, demonstrating that semaglutide significantly improved walking outcomes in people with PAD and diabetes, enhanced quality of life, and reduced the risk of disease progression by 54%. At week 52, the estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group. Semaglutide was well tolerated, with no treatment-related deaths and a low rate of serious adverse events (1%), consistent with its known safety profile. The analyses from STRIDE presented new and critical information on the benefits of semaglutide, which were observed independent of baseline levels of A1C, duration of diabetes, or intensity of diabetes. Furthermore, the benefits were seen across all BMI categories and regardless of the treatment with SGLT2 inhibitors. "These findings indicate that clinicians can now recognize semaglutide as a vascular protective medication, with benefits that extend beyond lowering weight or A1C," said Professor Subodh Verma, MD, PhD, FRCSC, FAHA, FCAHS, cardiovascular surgeon, University of Toronto, Toronto, Canada, and senior author of the STRIDE trial. "The totality of data now suggest that in people with diabetes, semaglutide favorably affects the pipes [atherosclerosis], pump [heart failure], filter [kidney outcomes]. And, in patients with PAD, these new data provide robust evidence that semaglutide is a therapy to improve their function, quality of life, and progression of disease."The study authors indicate that further research is warranted to understand whether these benefits extend to individuals with PAD who do not have diabetes. Research presentation details:Dr. Verma will present the findings at the following symposium: Symposium: Diabetes and Peripheral Artery Disease—Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial Presented on Saturday, June 21 at 1:30 p.m. CT About the ADA's Scientific SessionsThe ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Media Contact: Mimi Carmody, MCarmody@ View original content to download multimedia: SOURCE American Diabetes Association Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store